1. Home
  2. TRDA vs HRZN Comparison

TRDA vs HRZN Comparison

Compare TRDA & HRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TRDA

Entrada Therapeutics Inc.

HOLD

Current Price

$6.46

Market Cap

268.6M

Sector

Health Care

ML Signal

HOLD

Logo Horizon Technology Finance Corporation

HRZN

Horizon Technology Finance Corporation

HOLD

Current Price

$4.62

Market Cap

322.2M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRDA
HRZN
Founded
2016
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
268.6M
322.2M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
TRDA
HRZN
Price
$6.46
$4.62
Analyst Decision
Strong Buy
Hold
Analyst Count
3
5
Target Price
$21.00
$6.50
AVG Volume (30 Days)
345.9K
636.6K
Earning Date
05-08-2026
05-05-2026
Dividend Yield
N/A
33.85%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$25,421,000.00
N/A
Revenue This Year
$39.97
$12.25
Revenue Next Year
$50.80
$22.53
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.93
$3.80
52 Week High
$16.45
$8.46

Technical Indicators

Market Signals
Indicator
TRDA
HRZN
Relative Strength Index (RSI) 40.49 52.59
Support Level $5.75 $4.56
Resistance Level $7.02 $4.68
Average True Range (ATR) 0.46 0.12
MACD -0.06 -0.01
Stochastic Oscillator 13.87 43.07

Price Performance

Historical Comparison
TRDA
HRZN

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

About HRZN Horizon Technology Finance Corporation

Horizon Technology Finance Corp is a specialty finance company. Its investment objective is to maximize its investment portfolio's total return by generating current income from the debt investments it makes and capital appreciation from the warrants it receives when making such debt investments. It lends to and invests in development-stage companies in the technology, life science, healthcare information and services, and sustainability industries.

Share on Social Networks: